17:12 , May 17, 2019 |  BC Extra  |  Financial News

Tools4Patient raises €4M to refine, expand placebo response analytics

As it seeks to apply its placebo response measurement tool to new therapeutic areas beyond pain, Tools4Patient has tapped investors for a €4 million ($4.5 million) series B round. The company's Placebell technology uses an...
21:44 , May 7, 2019 |  BC Extra  |  Preclinical News

May 7 Preclinical Quick Takes: Single-cell computation, DARPA

Sensitive analysis of big single-cell data sets  A “geometric sketch” algorithm could be used to sensitively profile large sets of single-cell RNA sequencing data without sacrificing transcriptional diversity, according to a study from Massachusetts Institute...
18:03 , May 2, 2019 |  BC Innovations  |  Translation in Brief

From MSI-high to MSI-higher

A study in Science offers more clues to the consistent but poorly defined link between tumor mutation load and checkpoint inhibitor response. The data could explain why less than half of patients with MSI-high status...
19:16 , Apr 26, 2019 |  BioCentury  |  Product Development

For patients’ sake, collaborate already

Cancer immunotherapy companies must stop squandering the most precious stakeholder, patients, and collaborate now on platform trials to test new combination regimens. A straightforward platform trial design that tests different combo partners with PD-1/PD-L1 agents...
22:58 , Apr 25, 2019 |  BC Innovations  |  Emerging Company Profile

Cell Mogrify directly reprograms cells in vivo

Mogrify is jumping ahead of the technologies that have propelled the stem cell field by creating a platform that bypasses intermediate steps, and opens the door to in vivo reprogramming. Cell Mogrify Ltd. uses small...
17:18 , Apr 25, 2019 |  BC Innovations  |  Emerging Company Profile

miR Scientific: spotting aggression with RNA in urine

miR has paired its panel of urine-based RNAs with a statistical algorithm for accurate diagnosis of aggressive bladder and prostate cancers, sparing patients with lower-grade tumors from invasive biopsies and unnecessary drug treatments. The company's...
11:00 , Apr 18, 2019 |  BioCentury  |  Finance

Arranging Arrakis' syndicate

As it raised a $75 million series B round that will help its early research coalesce into a preclinical pipeline, Arrakis sought an investor syndicate that would build its expertise as it seeks to become...
02:22 , Apr 5, 2019 |  BC Innovations  |  Tools & Techniques

Second shot for shRNA

Having long been demoted to tool compound status, shRNA is gaining renewed attention as a therapeutic modality by offering a simpler path to creating next-generation cell therapies than gene editing. Celyad has jumped in, using...
21:05 , Mar 25, 2019 |  BC Extra  |  Clinical News

Avanir's AVP-786 meets in Phase III for Alzheimer's agitation

Avanir said one of two doses of AVP-786 met the primary endpoint of improving agitation symptoms in the Phase III 15-AVP-786-301 trial to treat agitation in patients with Alzheimer's dementia. AVP-786 comprises deuterium-modified dextromethorphan --...
01:34 , Mar 23, 2019 |  BioCentury  |  Tools & Techniques

A frequentist and a Bayesian walk into a trial

In the stand-off between Bayesians and frequentists, the latter own the show for pivotal trials. But with non-profits leading the drive, Bayesians are poised to enter late-stage development via platform trials in cancer. The next...